Technical Guidance for Mc-Val-Cit-PABC-PNP in ADC Research

What This Product Solves

Antibody-drug conjugates (ADCs) demand linkers that allow for targeted payload release within the lysosome, minimizing off-target effects and maximizing delivery specificity. Mc-Val-Cit-PABC-PNP addresses this requirement as a cathepsin B-cleavable ADC peptide linker, widely used in research workflows that mimic lysosomal environments. Its structure is tailored for organic solvent-based conjugation protocols, facilitating robust lysosomal cleavage and ensuring payload release only after internalization by target cells. This design is critical for studies on targeted drug delivery mechanisms and linker stability in preclinical ADC development.

Protocol Parameters

• Assay: Stock Solution Preparation
  Value with Unit: ≥36.9 mg/mL in DMSO
  Applicability: Solubilization for conjugation and storage
  Rationale: The product is highly soluble in DMSO but insoluble in water and ethanol; DMSO ensures maximal stock concentration for efficient ADC synthesis.
  Source Type: product information
• Assay: Storage Temperature
  Value with Unit: -20°C (solid form recommended)
  Applicability: Long-term preservation of chemical integrity
  Rationale: Low temperatures minimize hydrolysis and degradation; solutions should be prepared fresh to avoid loss of activity.
  Source Type: product information
• Assay: Workflow Solvent Compatibility
  Value with Unit: Organic solvents only (e.g., DMSO)
  Applicability: ADC conjugation reactions
  Rationale: The linker is insoluble in water and ethanol, restricting its use to organic solvent-based protocols.
  Source Type: product information

Workflow Setup and QC Checklist

For consistent results during antibody-drug conjugate synthesis with Mc-Val-Cit-PABC-PNP, follow these workflow recommendations:

• Stock Preparation: Dissolve the linker in anhydrous DMSO to achieve a high-concentration stock (≥36.9 mg/mL). Avoid water and ethanol during solubilization to prevent precipitation.
• Aliquoting and Storage: Prepare aliquots of the solid compound and store at -20°C. Stock solutions should be used immediately after preparation. Do not subject solutions to freeze-thaw cycles.
• Conjugation Workflow: Integrate the linker into organic solvent-based ADC synthesis protocols. Ensure that buffer exchange steps fully remove aqueous content prior to linker addition.
• Purity Controls: Mc-Val-Cit-PABC-PNP is supplied at ≥98% purity. Validate purity via HPLC or MS if critical to downstream applications.
• QC Sampling: Prior to use in conjugation, inspect aliquots for signs of hydrolysis or precipitation. Discard solutions with visible changes or extended storage time.

For a detailed overview of workflow integration, the article "Mc-Val-Cit-PABC-PNP: Practical Guide for ADC Linker Workflows" provides stepwise handling and workflow-specific solubility guidance relevant to organic solvent-based protocols. Additionally, the article "Mc-Val-Cit-PABC-PNP: Practical Guide for ADC Linker Use" covers critical workflow boundaries and lysosomal-triggered payload release considerations.

Common Failure Modes and Fixes

• Precipitation During Stock Preparation: If the linker fails to dissolve, verify DMSO quality and ensure the absence of water. Warm gently if needed, but avoid prolonged heating.
• Loss of Activity After Storage: Avoid storing Mc-Val-Cit-PABC-PNP in solution for extended periods. Always use freshly prepared DMSO stocks. If activity loss is suspected, prepare new stocks from the solid form.
• Low Conjugation Efficiency: Confirm that all aqueous buffers have been removed from protein/antibody before linker addition. Residual water will cause precipitation and reduce yield.
• Unexpected Side Products: Assess for hydrolysis or decomposition if the linker has been exposed to moisture or incorrect temperature. Use analytical verification prior to conjugation.

Scope and Limitations

Mc-Val-Cit-PABC-PNP is intended for scientific research use only and should not be used in diagnostic, therapeutic, or clinical applications. Its utility is confined to workflows employing organic solvents, with documented incompatibility in aqueous or mixed-solvent systems. The product is not suitable for direct in vivo studies or for use in regulatory submissions, and all solution-based manipulations should be performed promptly to avoid degradation. For applications requiring cathepsin B substrate linkers in targeted drug delivery research, its performance is best realized in controlled lysosomal cleavage studies within the preclinical setting.

Conclusion

Mc-Val-Cit-PABC-PNP provides a reliable, cathepsin cleavable ADC peptide linker solution for targeted drug delivery research workflows that demand precise lysosomal payload release and strict control over conjugation conditions. Its solubility and storage profile require adherence to organic solvent protocols and prompt use of prepared solutions. For further technical data, refer to the Mc-Val-Cit-PABC-PNP product page at APExBIO.